Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.
The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future clinical studies.
Smalley
K S M
KS
The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania, 19104, USA. ksmalley@wistar.org
Contractor
R
R
Haass
N K
NK
Lee
J T
JT
Nathanson
K L
KL
Medina
C A
CA
Flaherty
K T
KT
Herlyn
M
M
D014408:Biomarkers, Tumor / Q000032:analysis*; D002070:Butadienes / Q000032:analysis; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D048049:Extracellular Signal-Regulated MAP Kinases / Q000032:analysis* / Q000037:antagonists & inhibitors*; D016193:G1 Phase; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis*; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors*; D009154:Mutation; D009570:Nitriles / Q000032:analysis; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics
D014408:Biomarkers, Tumor; D002070:Butadienes; D019394:Ki-67 Antigen; D009570:Nitriles; D000081082:Phosphoinositide-3 Kinase Inhibitors; C113580:U 0126; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D048049:Extracellular Signal-Regulated MAP Kinases; D020929:Mitogen-Activated Protein Kinase Kinases